Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H15NO |
Molecular Weight | 165.2322 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN[C@@H](C)[C@H](O)C1=CC=CC=C1
InChI
InChIKey=KWGRBVOPPLSCSI-WPRPVWTQSA-N
InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1
Molecular Formula | C10H15NO |
Molecular Weight | 165.2322 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:21:02 UTC 2023
by
admin
on
Fri Dec 15 17:21:02 UTC 2023
|
Record UNII |
GN83C131XS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
S01FB02
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
WHO-ATC |
R01AA03
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
WHO-VATC |
QC01CA26
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
WHO-ATC |
R03CA02
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
NDF-RT |
N0000175552
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
1.2
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
CFR |
21 CFR 119.1
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
WHO-VATC |
QR01AA03
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
CFR |
21 CFR 1315.13
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
WHO-ATC |
C01CA26
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
WHO-VATC |
QS01FB02
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
CFR |
21 CFR 341.20
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
NCI_THESAURUS |
C87053
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
NDF-RT |
N0000175555
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
WHO-VATC |
QG04BX90
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
NDF-RT |
N0000192563
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
DEA NO. |
8113
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
CFR |
21 CFR 341.16
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
WHO-ATC |
A08AA56
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
CFR |
21 CFR 1314.20
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
WHO-VATC |
QR03CA02
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
WHO-ATC |
R01AB05
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
||
|
WHO-VATC |
QR01AB05
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
170951
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
SUB13683MIG
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
DB01364
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
1024
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
100000088883
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
3072
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
D004809
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
206-080-5
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
9294
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
EPHEDRINE
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
8971
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
SUB11936MIG
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
GN83C131XS
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
C472
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
m4933
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | Merck Index | ||
|
299-42-3
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
EPHEDRINE
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | Description: Colourless crystals or a white, crystalline powder; odourless or with a slight, aromatic odour.Solubility: Soluble in water; very soluble in ethanol (~750 g/l) TS; freely soluble in ether R.Category: Antiasthmatic drug.Storage: Ephedrine should be kept in a well-closed container, protected from light.Labelling: The designation on the container should state whether the substance is the hemihydrate or is in the anhydrous form.Additional information. Solutions of Ephedrine in chloroform R may become turbid, especially when the substance contains morethan 10 mg of water per g. Even in the absence of light, Ephedrine is gradually degraded on exposure to a humid atmosphere,the decomposition being faster at higher temperatures. Anhydrous Ephedrine melts at about 38?C, whereas Ephedrinehemihydrate melts at about 42?C. | ||
|
GN83C131XS
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
3966
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | RxNorm | ||
|
556
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
DTXSID0022985
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
CHEMBL211456
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY | |||
|
15407
Created by
admin on Fri Dec 15 17:21:03 UTC 2023 , Edited by admin on Fri Dec 15 17:21:03 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT->PRECURSOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
DIASTEREOISOMER -> DIASTEREOISOMER |
|
||
|
DIASTEREOISOMER -> DIASTEREOISOMER |
|
||
|
DIASTEREOISOMER -> DIASTEREOISOMER |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SOLVATE->ANHYDROUS |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT->PRECURSOR |
|
||
|
SALT/SOLVATE -> PARENT |
Definition. Ephedrine contains not less than 98.5% and not more than 101.0% of C10H15NO, calculated with reference to the anhydrous substance.
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
DIASTEREOISOMER -> DIASTEREOISOMER |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
ASSAY (HPLC)
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|